

Supplementary Table S2. Full risk model for progression to advanced age-related macular degeneration (AMD), geographic atrophy (GA) and neovascular disease (NV)

	Advanced AMD (948/5421 eyes)		GA (487/5421 eyes)		NV (495/5421 eyes)	
	ESTIMATES (±SE)*	P value	ESTIMATES (±SE)*	P value	ESTIMATES (±SE)*	P value
Demographic						
male	0.03 (±0.08)	0.69	0.19 (±0.11)	0.068	-0.15 (±0.11)	0.15
white	0.68 (±0.36)	0.06	1.99 (±1.03)	0.053	0.17 (±0.41)	0.67
> high school	-0.04 (±0.07)	0.61	0.07 (±0.11)	0.53	-0.15 (±0.11)	0.17
Behavioral						
Current smoker	0.96 (±0.13)	<0.001	0.74 (±0.2)	0.0002	0.98 (±0.19)	<0.001
Past smoker	0.14 (±0.08)	0.088	0.06 (±0.11)	0.61	0.28 (±0.11)	0.011
BMI 25-29	0.15 (±0.09)	0.078	0.14 (±0.12)	0.26	0.19 (±0.12)	0.14
BMI ≥30	0.28 (±0.1)	0.003	0.25 (±0.14)	0.06	0.32 (±0.14)	0.018
Baseline Severity Scale						
1						
2	1.46 (±0.3)	<0.001	2.39 (±0.65)	0.0002	1.08 (±0.34)	0.002
3	1.77 (±0.32)	<0.001	2.66 (±0.62)	<0.001	1.46 (±0.36)	<0.001
4	2.60 (±0.25)	<0.001	3.29 (±0.62)	<0.001	2.32 (±0.29)	<0.001
5	3.26 (±0.26)	<0.001	4.21 (±0.6)	<0.001	2.88 (±0.28)	<0.001
6	3.69 (±0.25)	<0.001	4.70 (±0.6)	<0.001	3.27 (±0.28)	<0.001
7	4.31 (±0.25)	<0.001	5.73 (±0.59)	<0.001	3.27 (±0.28)	<0.001
8	4.63 (±0.25)	<0.001	6.14 (±0.59)	<0.001	3.37 (±0.3)	<0.001
Genetic variants						
Complement pathway						
<i>CFH</i> Y402H: rs1061170					0.27 (±0.07)	<0.001
<i>CFH</i> : rs1410996	0.29 (±0.07)	<0.001	0.29 (±0.1)	0.003		
<i>CFH</i> R1210C: rs121913059	1.08 (±0.26)	<0.001	0.91 (±0.44)	0.037	1.04 (±0.3)	<0.001

<i>C3</i> R102G: rs2230199	0.15 (±0.06)	0.007			0.17 (±0.08)	0.033
<i>C3</i> K155Q: rs147859257	0.70 (±0.16)	<0.001	0.83 (±0.19)	<0.001		
Angiogenesis pathway						
<i>TGFBR1</i> : rs334353					-0.18 (±0.09)	0.044
Immune/inflammatory pathway						
<i>ARMS2/HTRA1</i> : rs10490924	0.36 (±0.05)	<0.001	0.22 (±0.07)	0.002	0.50 (±0.07)	<0.001
<i>TNFRSF10A</i> : rs13278062					-0.13 (±0.07)	0.066
Extracellular matrix						
<i>COL8A1</i> : rs13095226	0.17 (±0.08)	0.023	0.24 (±0.11)	0.028		
DNA repair/protein binding						
<i>RAD51B</i> : rs8017304	-0.20 (±0.06)	<0.001			-0.27 (±0.08)	<0.001
<i>HSPH1/B3GALTL</i> : rs9542236	0.12 (±0.05)	0.019			0.15 (±0.07)	0.038

* Estimates were calculated for time to progression using age as the time scale with eyes as the unit of analysis, adjusted for sex, race, education, smoking history, BMI, AMD baseline eye-specific severity scale, AREDS treatment, and the genetic variants associated with the respective outcome.
